CN115252910A - 脂肪组织产品以及产生方法 - Google Patents
脂肪组织产品以及产生方法 Download PDFInfo
- Publication number
- CN115252910A CN115252910A CN202210669481.XA CN202210669481A CN115252910A CN 115252910 A CN115252910 A CN 115252910A CN 202210669481 A CN202210669481 A CN 202210669481A CN 115252910 A CN115252910 A CN 115252910A
- Authority
- CN
- China
- Prior art keywords
- tissue
- matrix
- adipose tissue
- particles
- adipose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 111
- 238000000034 method Methods 0.000 title claims abstract description 85
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 210000001519 tissue Anatomy 0.000 claims abstract description 211
- 239000000463 material Substances 0.000 claims abstract description 114
- 239000002245 particle Substances 0.000 claims description 80
- 238000004132 cross linking Methods 0.000 claims description 26
- 238000003754 machining Methods 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 13
- 230000001413 cellular effect Effects 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 10
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 claims description 3
- 150000001718 carbodiimides Chemical class 0.000 claims description 3
- 125000005442 diisocyanate group Chemical group 0.000 claims description 3
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 54
- 238000002347 injection Methods 0.000 abstract description 19
- 239000007924 injection Substances 0.000 abstract description 19
- 238000002513 implantation Methods 0.000 abstract description 10
- 230000001172 regenerating effect Effects 0.000 abstract description 4
- 210000004872 soft tissue Anatomy 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 115
- 239000011159 matrix material Substances 0.000 description 107
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 91
- 229920002674 hyaluronan Polymers 0.000 description 91
- 229960003160 hyaluronic acid Drugs 0.000 description 91
- 239000003925 fat Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 31
- 230000009969 flowable effect Effects 0.000 description 31
- 150000002632 lipids Chemical class 0.000 description 21
- 239000007787 solid Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- 102000008186 Collagen Human genes 0.000 description 16
- 108010035532 Collagen Proteins 0.000 description 16
- 229920001436 collagen Polymers 0.000 description 16
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 14
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 14
- 230000002500 effect on skin Effects 0.000 description 12
- 239000002002 slurry Substances 0.000 description 12
- 238000000227 grinding Methods 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 238000010186 staining Methods 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000010894 electron beam technology Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 230000006641 stabilisation Effects 0.000 description 8
- 238000011105 stabilization Methods 0.000 description 8
- 102000029816 Collagenase Human genes 0.000 description 7
- 108060005980 Collagenase Proteins 0.000 description 7
- 229960002424 collagenase Drugs 0.000 description 7
- 239000003431 cross linking reagent Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 108060003393 Granulin Proteins 0.000 description 5
- 230000002293 adipogenic effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 238000005549 size reduction Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000003416 augmentation Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000008512 biological response Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000011759 adipose tissue development Effects 0.000 description 3
- 238000004630 atomic force microscopy Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000005238 degreasing Methods 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229940014041 hyaluronate Drugs 0.000 description 3
- 230000000887 hydrating effect Effects 0.000 description 3
- 229940050561 matrix product Drugs 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- -1 phenylene bis- (ethyl) Chemical group 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- PGMKGZOHRBZSSQ-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethenoxymethyl]oxirane Chemical group C1OC1COC=COCC1CO1 PGMKGZOHRBZSSQ-UHFFFAOYSA-N 0.000 description 2
- PLDLPVSQYMQDBL-UHFFFAOYSA-N 2-[[3-(oxiran-2-ylmethoxy)-2,2-bis(oxiran-2-ylmethoxymethyl)propoxy]methyl]oxirane Chemical compound C1OC1COCC(COCC1OC1)(COCC1OC1)COCC1CO1 PLDLPVSQYMQDBL-UHFFFAOYSA-N 0.000 description 2
- XOBTWQWSFMZPNQ-UHFFFAOYSA-N 5-(oxiran-2-ylmethyl)-7-oxabicyclo[4.1.0]heptane Chemical compound C1CCC2OC2C1CC1CO1 XOBTWQWSFMZPNQ-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 2
- 238000002737 cell proliferation kit Methods 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940025708 injectable product Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- LFKLPJRVSHJZPL-UHFFFAOYSA-N 1,2:7,8-diepoxyoctane Chemical compound C1OC1CCCCC1CO1 LFKLPJRVSHJZPL-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000989913 Gunnera petaloidea Species 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- QIGJYVCQYDKYDW-SDOYDPJRSA-N alpha-D-galactosyl-(1->3)-D-galactose Chemical group O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-SDOYDPJRSA-N 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000000604 fetal stem cell Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 229960004288 levobupivacaine Drugs 0.000 description 1
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- IYFWKMMMFIDAQJ-UHFFFAOYSA-N n-ethyl-n'-[6-(ethyliminomethylideneamino)hexyl]methanediimine Chemical compound CCN=C=NCCCCCCN=C=NCC IYFWKMMMFIDAQJ-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 229950003255 propoxycaine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940072040 tricaine Drugs 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/04—Materials or treatment for tissue regeneration for mammary reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573892P | 2017-10-18 | 2017-10-18 | |
| US62/573,892 | 2017-10-18 | ||
| PCT/US2018/056473 WO2019079570A1 (en) | 2017-10-18 | 2018-10-18 | ADIPOSE TISSUE PRODUCTS AND METHODS OF PRODUCTION |
| CN201880065592.1A CN111201046B (zh) | 2017-10-18 | 2018-10-18 | 脂肪组织产品以及产生方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880065592.1A Division CN111201046B (zh) | 2017-10-18 | 2018-10-18 | 脂肪组织产品以及产生方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115252910A true CN115252910A (zh) | 2022-11-01 |
Family
ID=64267918
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210669481.XA Pending CN115252910A (zh) | 2017-10-18 | 2018-10-18 | 脂肪组织产品以及产生方法 |
| CN201880065592.1A Active CN111201046B (zh) | 2017-10-18 | 2018-10-18 | 脂肪组织产品以及产生方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880065592.1A Active CN111201046B (zh) | 2017-10-18 | 2018-10-18 | 脂肪组织产品以及产生方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10821205B2 (https=) |
| EP (2) | EP4541385A3 (https=) |
| JP (4) | JP7297739B2 (https=) |
| CN (2) | CN115252910A (https=) |
| AU (3) | AU2018351051A1 (https=) |
| CA (1) | CA3075099A1 (https=) |
| WO (1) | WO2019079570A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016001247A (es) | 2013-07-30 | 2016-08-17 | Musculoskeletal Transplant Foundation | Matrices derivadas de tejido suave acelular y metodos para preparar las mismas. |
| US10912864B2 (en) | 2015-07-24 | 2021-02-09 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
| US11123375B2 (en) | 2017-10-18 | 2021-09-21 | Lifecell Corporation | Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products |
| WO2019079570A1 (en) * | 2017-10-18 | 2019-04-25 | Lifecell Corporation | ADIPOSE TISSUE PRODUCTS AND METHODS OF PRODUCTION |
| WO2019079672A1 (en) | 2017-10-19 | 2019-04-25 | Lifecell Corporation | ACELLULAR TISSUE MATRIX PRODUCTS FLUIDS AND METHODS OF PRODUCTION |
| US11246994B2 (en) | 2017-10-19 | 2022-02-15 | Lifecell Corporation | Methods for introduction of flowable acellular tissue matrix products into a hand |
| ES3056561T3 (en) * | 2019-05-30 | 2026-02-23 | Lifecell Corp | Biologic breast implant |
| WO2021003321A1 (en) * | 2019-07-03 | 2021-01-07 | Lifecell Corporation | Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products |
| US20210052774A1 (en) * | 2019-08-21 | 2021-02-25 | Lifecell Corporation | Fixed-shape tissue matrix and related methods |
| KR102433259B1 (ko) * | 2019-12-17 | 2022-08-17 | 주식회사 엘앤씨바이오 | 지방조직 유래 세포외기질을 포함하는 의료용 조성물 및 그 제조방법 |
| WO2021125373A1 (ko) * | 2019-12-17 | 2021-06-24 | 주식회사 엘앤씨바이오 | 지방조직 유래 세포외기질을 포함하는 의료용 조성물 및 그 제조방법 |
| EP4233897A4 (en) * | 2020-10-23 | 2024-10-02 | SK Bioscience Co., Ltd. | Vaccine composition or kit for reducing size or volume of target tissue, containing genetic material that encodes foreign antigen |
| EP4052734B1 (en) * | 2021-03-02 | 2024-04-24 | Solidified Inc. | Immunocompatible tissue scaffold and methods of forming the same |
| US12351620B1 (en) | 2023-05-03 | 2025-07-08 | Humabiologics, Inc. | Process for production of a soluble and insoluble collagen product from mammalian dermis tissue |
| US12351621B1 (en) | 2023-05-03 | 2025-07-08 | Humabiologics, Inc. | Composite collagen product and method of making thereof |
| US12134792B1 (en) | 2023-05-03 | 2024-11-05 | Humabiologics, Inc. | Process for production of a soluble and insoluble collagen product from mammalian dermis tissue |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101161298A (zh) * | 2007-11-20 | 2008-04-16 | 郑隆泗 | 一种以明胶为原料制备明胶海绵颗粒栓塞剂的工艺 |
| CN101574539A (zh) * | 2009-06-15 | 2009-11-11 | 北京大学 | 一种明胶海绵及其制备方法 |
| CN101991875A (zh) * | 2010-10-29 | 2011-03-30 | 上海硅健生物材料有限公司 | 介孔生物活性玻璃和壳聚糖复合多孔止血材料及制备方法 |
| CN102575229A (zh) * | 2009-08-11 | 2012-07-11 | 约翰霍普金斯大学 | 用于植入经加工的脂肪组织和经加工的脂肪组织产品的组合物和方法 |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1562244A (en) | 1976-11-11 | 1980-03-05 | Lock P M | Wound dressing materials |
| US4569348A (en) | 1980-02-22 | 1986-02-11 | Velcro Usa Inc. | Catheter tube holder strap |
| US4373519A (en) | 1981-06-26 | 1983-02-15 | Minnesota Mining And Manufacturing Company | Composite wound dressing |
| US4582640A (en) | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
| IL74715A0 (en) | 1984-03-27 | 1985-06-30 | Univ New Jersey Med | Biodegradable matrix and methods for producing same |
| US4969912A (en) | 1988-02-18 | 1990-11-13 | Kelman Charles D | Human collagen processing and autoimplant use |
| US4950483A (en) | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US5024841A (en) | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US4902508A (en) | 1988-07-11 | 1990-02-20 | Purdue Research Foundation | Tissue graft composition |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| CA2002261A1 (en) | 1988-11-07 | 1990-05-07 | Andreas Sommer | High molecular weight human angiogenic factors |
| JP2719671B2 (ja) | 1989-07-11 | 1998-02-25 | 日本ゼオン株式会社 | 創傷被覆材 |
| US5290558A (en) | 1989-09-21 | 1994-03-01 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
| US5131850A (en) | 1989-11-03 | 1992-07-21 | Cryolife, Inc. | Method for cryopreserving musculoskeletal tissues |
| US5104957A (en) | 1990-02-28 | 1992-04-14 | Autogenesis Technologies, Inc. | Biologically compatible collagenous reaction product and articles useful as medical implants produced therefrom |
| US8067149B2 (en) | 1990-09-12 | 2011-11-29 | Lifecell Corporation | Acellular dermal matrix and method of use thereof for grafting |
| US5336616A (en) | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
| CA2051092C (en) | 1990-09-12 | 2002-07-23 | Stephen A. Livesey | Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions |
| US5231169A (en) | 1990-10-17 | 1993-07-27 | Norian Corporation | Mineralized collagen |
| US5263971A (en) | 1991-02-13 | 1993-11-23 | Life Medical Sciences, Inc. | Apparatus for the closure of wide skin defects by stretching of skin |
| US5254133A (en) | 1991-04-24 | 1993-10-19 | Seid Arnold S | Surgical implantation device and related method of use |
| US5149331A (en) | 1991-05-03 | 1992-09-22 | Ariel Ferdman | Method and device for wound closure |
| US5160313A (en) | 1991-05-14 | 1992-11-03 | Cryolife, Inc. | Process for preparing tissue for transplantation |
| US7198046B1 (en) | 1991-11-14 | 2007-04-03 | Wake Forest University Health Sciences | Wound treatment employing reduced pressure |
| US5645081A (en) | 1991-11-14 | 1997-07-08 | Wake Forest University | Method of treating tissue damage and apparatus for same |
| US5636643A (en) | 1991-11-14 | 1997-06-10 | Wake Forest University | Wound treatment employing reduced pressure |
| US5275826A (en) | 1992-11-13 | 1994-01-04 | Purdue Research Foundation | Fluidized intestinal submucosa and its use as an injectable tissue graft |
| US5641518A (en) | 1992-11-13 | 1997-06-24 | Purdue Research Foundation | Method of repairing bone tissue |
| US5437651A (en) | 1993-09-01 | 1995-08-01 | Research Medical, Inc. | Medical suction apparatus |
| US5549584A (en) | 1994-02-14 | 1996-08-27 | The Kendall Company | Apparatus for removing fluid from a wound |
| ATE265191T1 (de) | 1994-03-14 | 2004-05-15 | Cryolife Inc | Herstellungsverfahren von gewebe zur implantation |
| US5489304A (en) | 1994-04-19 | 1996-02-06 | Brigham & Women's Hospital | Method of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft |
| US5906827A (en) | 1994-06-03 | 1999-05-25 | Creative Biomolecules, Inc. | Matrix for the manufacture of autogenous replacement body parts |
| US5599852A (en) | 1994-10-18 | 1997-02-04 | Ethicon, Inc. | Injectable microdispersions for soft tissue repair and augmentation |
| US5622867A (en) | 1994-10-19 | 1997-04-22 | Lifecell Corporation | Prolonged preservation of blood platelets |
| US6485723B1 (en) | 1995-02-10 | 2002-11-26 | Purdue Research Foundation | Enhanced submucosal tissue graft constructs |
| US5834232A (en) | 1996-05-01 | 1998-11-10 | Zymogenetics, Inc. | Cross-linked gelatin gels and methods of making them |
| US6666892B2 (en) | 1996-08-23 | 2003-12-23 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
| US6066325A (en) | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
| US8603511B2 (en) * | 1996-08-27 | 2013-12-10 | Baxter International, Inc. | Fragmented polymeric compositions and methods for their use |
| US6998418B1 (en) | 1996-11-05 | 2006-02-14 | Gp Medical, Inc. | Acellular biological material chemically treated with genipin |
| US6096347A (en) | 1996-11-05 | 2000-08-01 | Purdue Research Foundation | Myocardial graft constructs |
| AUPO599897A0 (en) | 1997-04-03 | 1997-05-01 | Vidal, Linus | Clear collagen for facial implants |
| US5993844A (en) | 1997-05-08 | 1999-11-30 | Organogenesis, Inc. | Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix |
| US6135116A (en) | 1997-07-28 | 2000-10-24 | Kci Licensing, Inc. | Therapeutic method for treating ulcers |
| US6613278B1 (en) | 1998-11-13 | 2003-09-02 | Regeneration Technologies, Inc. | Tissue pooling process |
| GB9719520D0 (en) | 1997-09-12 | 1997-11-19 | Kci Medical Ltd | Surgical drape and suction heads for wound treatment |
| US6371992B1 (en) | 1997-12-19 | 2002-04-16 | The Regents Of The University Of California | Acellular matrix grafts: preparation and use |
| US6071267A (en) | 1998-02-06 | 2000-06-06 | Kinetic Concepts, Inc. | Medical patient fluid management interface system and method |
| US6326018B1 (en) | 1998-02-27 | 2001-12-04 | Musculoskeletal Transplant Foundation | Flexible sheet of demineralized bone |
| US20030039678A1 (en) | 1998-03-16 | 2003-02-27 | Stone Kevin R. | Xenograft bone matrix for orthopedic applications |
| US6179872B1 (en) | 1998-03-17 | 2001-01-30 | Tissue Engineering | Biopolymer matt for use in tissue repair and reconstruction |
| US6432710B1 (en) | 1998-05-22 | 2002-08-13 | Isolagen Technologies, Inc. | Compositions for regenerating tissue that has deteriorated, and methods for using such compositions |
| JP2002516254A (ja) | 1998-05-26 | 2002-06-04 | ライフセル コーポレイション | ヒト赤血球の低温保存 |
| US6933326B1 (en) | 1998-06-19 | 2005-08-23 | Lifecell Coporation | Particulate acellular tissue matrix |
| CA2335686C (en) | 1998-06-19 | 2008-11-18 | Lifecell Corporation | Particulate acellular tissue matrix |
| WO2000016822A1 (en) | 1998-09-21 | 2000-03-30 | The Brigham And Women's Hospital, Inc. | Compositions and methods for tissue repair |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| WO2000047114A1 (en) | 1999-02-12 | 2000-08-17 | Collagenesis, Inc. | Injectable collagen-based delivery system for bone morphogenic proteins |
| US6856821B2 (en) | 2000-05-26 | 2005-02-15 | Kci Licensing, Inc. | System for combined transcutaneous blood gas monitoring and vacuum assisted wound closure |
| US6599318B1 (en) | 1999-11-30 | 2003-07-29 | Shlomo Gabbay | Implantable support apparatus and method of using same |
| US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
| MXPA03002414A (es) | 2000-09-18 | 2004-07-08 | Organogenesis Inc | Protesis con injerto de hoja plana tratada por bioingenieria y su uso. |
| IL139708A0 (en) | 2000-11-15 | 2002-02-10 | Amiel Gilad | Process of decellularizing biological matrices and acellular biological matrices useful in tissue engineering |
| US7070584B2 (en) | 2001-02-20 | 2006-07-04 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7153518B2 (en) | 2001-08-27 | 2006-12-26 | Regeneration Technologies, Inc. | Processed soft tissue for topical or internal application |
| JP4451658B2 (ja) | 2001-10-18 | 2010-04-14 | ライフセル コーポレーション | 組織および器官のリモデリング |
| WO2003072157A1 (en) | 2002-02-21 | 2003-09-04 | Encelle, Inc. | Immobilized bioactive hydrogel matrices as surface coatings |
| WO2003080119A1 (en) | 2002-03-26 | 2003-10-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Responsive biomedical composites |
| US20030225347A1 (en) | 2002-06-03 | 2003-12-04 | Argenta Louis C. | Directed tissue growth employing reduced pressure |
| US7498040B2 (en) | 2005-10-12 | 2009-03-03 | Lifenet Health | Compositions for repair of defects in osseous tissues, and methods of making the same |
| US20040037735A1 (en) | 2002-08-23 | 2004-02-26 | Depaula Carl Alexander | Allograft tissue purification process for cleaning bone |
| US6840960B2 (en) | 2002-09-27 | 2005-01-11 | Stephen K. Bubb | Porous implant system and treatment method |
| US7402319B2 (en) | 2002-09-27 | 2008-07-22 | Board Of Regents, The University Of Texas System | Cell-free tissue replacement for tissue engineering |
| US7824701B2 (en) | 2002-10-18 | 2010-11-02 | Ethicon, Inc. | Biocompatible scaffold for ligament or tendon repair |
| US7115100B2 (en) | 2002-11-15 | 2006-10-03 | Ethicon, Inc. | Tissue biopsy and processing device |
| FR2856305B1 (fr) | 2003-06-19 | 2007-08-24 | Inst Nat Sante Rech Med | Protheses avec revetements biologiquement actifs |
| EP2399990B1 (en) | 2003-06-27 | 2015-07-22 | DePuy Synthes Products, Inc. | Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system |
| WO2005009134A1 (en) | 2003-07-21 | 2005-02-03 | Lifecell Corporation | ACELLULAR TISSUE MATRICES MADE FROM GALACTOSE α-1,3-GALACTOSE-DEFICIENT TISSUE |
| US7901461B2 (en) | 2003-12-05 | 2011-03-08 | Ethicon, Inc. | Viable tissue repair implants and methods of use |
| CN104721883A (zh) | 2004-03-17 | 2015-06-24 | 雷维维科公司 | 来源于缺乏任何功能性α1,3半乳糖基转移酶表达的动物的组织产品 |
| KR100680134B1 (ko) | 2004-06-10 | 2007-02-08 | 박우삼 | 무세포 진피를 주사가능하도록 입자 형태로 가공한 필러 |
| US20060058892A1 (en) | 2004-09-16 | 2006-03-16 | Lesh Michael D | Valved tissue augmentation implant |
| US20060073592A1 (en) | 2004-10-06 | 2006-04-06 | Wendell Sun | Methods of storing tissue matrices |
| US7905826B2 (en) | 2004-11-03 | 2011-03-15 | Cook Incorporated | Methods for modifying vascular vessel walls |
| DE102005002644A1 (de) | 2005-01-19 | 2006-07-20 | Schülke & Mayr GmbH | Zusammensetzungen für die hygienische Händedesinfektion und die desinfizierende Händewaschung |
| CA2604856A1 (en) | 2005-04-25 | 2006-11-02 | Eric F. Bernstein | Dermal fillers for biomedical applications in mammals and methods of using the same |
| ES2668551T3 (es) | 2005-09-26 | 2018-05-18 | Lifecell Corporation | Composición seca de plaquetas |
| US7498041B2 (en) | 2005-10-12 | 2009-03-03 | Lifenet Health | Composition for repair of defects in osseous tissues |
| JP5002805B2 (ja) | 2005-10-14 | 2012-08-15 | 財団法人ヒューマンサイエンス振興財団 | 生物由来スキャフォールドの作製方法 |
| US8029498B2 (en) | 2006-03-14 | 2011-10-04 | Kci Licensing Inc. | System for percutaneously administering reduced pressure treatment using balloon dissection |
| US9456860B2 (en) | 2006-03-14 | 2016-10-04 | Kci Licensing, Inc. | Bioresorbable foaming tissue dressing |
| US20070248575A1 (en) | 2006-04-19 | 2007-10-25 | Jerome Connor | Bone graft composition |
| EP2722425B1 (en) | 2006-04-24 | 2016-01-20 | Coloplast A/S | Gelatin non-woven structures produced by a non-toxic dry solvent spinning process |
| ES2720582T3 (es) | 2006-05-09 | 2019-07-23 | Lifecell Corp | Tejido biológico reforzado |
| JP5050197B2 (ja) | 2006-07-31 | 2012-10-17 | 財団法人ヒューマンサイエンス振興財団 | 生物由来スキャフォールドの作製方法 |
| SG175690A1 (en) | 2006-11-09 | 2011-11-28 | Kci Licensing Inc | Porous bioresorbable dressing conformable to a wound and methods of making same |
| JP5385257B2 (ja) * | 2007-03-26 | 2014-01-08 | バクスター・インターナショナル・インコーポレイテッド | 軟部組織増強のための注入可能な空隙の充填剤 |
| CA2685048A1 (en) | 2007-04-26 | 2008-11-06 | Advanced Technologies And Regenerative Medicine, Llc | Tissue engineering devices and methods for luminal organs |
| US9034367B2 (en) | 2007-05-10 | 2015-05-19 | Cormatrix Cardiovascular, Inc. | Articles for tissue regeneration with biodegradable polymer |
| RU2447878C2 (ru) | 2007-06-29 | 2012-04-20 | КейСиАй Лайсензинг Инк. | Активация образования костей и хрящей |
| JP5538217B2 (ja) | 2007-07-10 | 2014-07-02 | ライフセル コーポレーション | 組織修復用無細胞組織基質構成体 |
| US20090024224A1 (en) | 2007-07-16 | 2009-01-22 | Chen Silvia S | Implantation of cartilage |
| US9161970B2 (en) * | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
| US9782300B2 (en) | 2008-02-01 | 2017-10-10 | Kci Licensing, Inc. | Fiber-microsphere bioresorbable composite scaffold for wound healing |
| US8372060B2 (en) | 2008-05-13 | 2013-02-12 | Kci Licensing, Inc. | Catheter/filament style device and methods for treatment of wounds beneath the surface of the skin |
| CA2726350C (en) | 2008-06-06 | 2016-07-19 | Lifecell Corporation | Elastase treatment of tissue matrices |
| TW201000162A (en) | 2008-06-25 | 2010-01-01 | Kci Licensing Inc | Absorbable, reduced-pressure manifolds and systems |
| WO2009158480A2 (en) | 2008-06-26 | 2009-12-30 | Kci Licensing, Inc. | Stimulation of cartilage formation using reduced pressure treatment |
| EP3744357A1 (en) | 2008-08-14 | 2020-12-02 | 3M Innovative Properties Company | Tissue scaffolds |
| US7927414B2 (en) | 2008-09-05 | 2011-04-19 | Ethicon, Inc. | Method of manufacturing acellular matrix glue |
| JP5784500B2 (ja) | 2008-11-21 | 2015-09-24 | ライフセル コーポレーションLifeCell Corporation | 強化型生物由来物質 |
| WO2010078353A2 (en) | 2008-12-31 | 2010-07-08 | Kci Licensing, Inc. | Systems for providing fluid flow to tissues |
| WO2010078358A2 (en) | 2008-12-31 | 2010-07-08 | Kcl Licensing, Inc. | Systems for inducing fluid flow to stimulate tissue growth |
| KR20110102921A (ko) | 2008-12-31 | 2011-09-19 | 케이씨아이 라이센싱 인코포레이티드 | 조직 롤 스캐폴드 |
| US20110020271A1 (en) | 2009-05-20 | 2011-01-27 | Humacyte, Inc. | Elastin for soft tissue augmentation |
| MX2012006759A (es) * | 2009-12-17 | 2012-07-30 | Univ Kingston | Tejido adiposo descelularizado. |
| JP5818372B2 (ja) | 2010-01-22 | 2015-11-18 | ケーシーアイ ライセンシング インク | 陰圧創傷療法に関する発泡流体灌注デバイス、システムおよび方法 |
| US8632512B2 (en) | 2010-04-09 | 2014-01-21 | Kci Licensing, Inc. | Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds |
| US9636435B2 (en) | 2010-07-08 | 2017-05-02 | Lifecell Corporation | Method for shaping tissue matrices |
| ES2662331T3 (es) | 2010-08-10 | 2018-04-06 | Lifecell Corporation | Matrices tisulares regenerativas |
| CN102068714A (zh) * | 2011-01-19 | 2011-05-25 | 北京大学 | 一种胶原海绵及其制备方法 |
| CA2832838C (en) | 2011-04-14 | 2019-08-13 | Lifecell Corporation | Regenerative tissue matrix flakes |
| CN103534346A (zh) * | 2011-04-21 | 2014-01-22 | 细胞移植组织工程有限公司 | 细胞合成颗粒 |
| AU2012262311B2 (en) * | 2011-05-31 | 2016-04-28 | Lifecell Corporation | Adipose tissue matrices |
| MX353955B (es) | 2011-10-11 | 2018-02-07 | Allergan Holdings France Sas | Hebras de acido hialuronico reticulado y metodos de uso de las mismas. |
| CA2890366A1 (en) | 2011-11-09 | 2013-05-16 | Trustees Of Tufts College | Injectable silk fibroin particles and uses thereof |
| US20130121970A1 (en) * | 2011-11-10 | 2013-05-16 | Lifecell Corporation | Method for elimination of space through tissue approximation |
| ES2729712T3 (es) | 2011-12-20 | 2019-11-05 | Lifecell Corp | Productos de tejido de lámina |
| WO2013096252A1 (en) | 2011-12-20 | 2013-06-27 | Lifecell Corporation | Flowable tissue products |
| US9999637B2 (en) | 2012-04-24 | 2018-06-19 | Lifecell Corporation | Functionalized tissue matrices |
| AU2013251800B2 (en) | 2012-04-24 | 2016-09-29 | Lifecell Corporation | Flowable tissue matrices |
| WO2014144215A1 (en) | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Injectable composition for in-situ repair and regeneration of an injured ligament or tendon and methods of use |
| FR3006689A1 (fr) * | 2013-06-11 | 2014-12-12 | Benedicte Vincente Tauzin | Procede de reticulation de l'acide hyaluronique; procede de preparation d'un hydrogel injectable; hydrogel obtenu; utilisation de l'hydroget obtenu |
| WO2015048317A1 (en) | 2013-09-25 | 2015-04-02 | The Children's Mercy Hospital | Decellularized hyaline cartilage powder for tissue scaffolds |
| US20160089477A1 (en) * | 2014-09-25 | 2016-03-31 | Acell, Inc. | Porous foams derived from extracellular matrix, porous foam ecm medical devices, and methods of use and making thereof |
| KR101729127B1 (ko) * | 2014-10-24 | 2017-04-26 | 주식회사 엘앤씨바이오 | 입자형 무세포 진피와 히알루론산이 전자빔을 통해 물리적으로 가교된 생체 이식용 조성물의 제조방법 |
| US20170021058A1 (en) * | 2015-07-24 | 2017-01-26 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
| GB201514788D0 (en) * | 2015-08-20 | 2015-10-07 | Ecole Polytech | Malleable scaffold material and uses thereof |
| CA3012849A1 (en) | 2016-02-08 | 2017-08-17 | Lifecell Corporation | Biologic breast implant |
| WO2019079570A1 (en) * | 2017-10-18 | 2019-04-25 | Lifecell Corporation | ADIPOSE TISSUE PRODUCTS AND METHODS OF PRODUCTION |
| US11123375B2 (en) | 2017-10-18 | 2021-09-21 | Lifecell Corporation | Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products |
| WO2019079672A1 (en) | 2017-10-19 | 2019-04-25 | Lifecell Corporation | ACELLULAR TISSUE MATRIX PRODUCTS FLUIDS AND METHODS OF PRODUCTION |
| US11246994B2 (en) | 2017-10-19 | 2022-02-15 | Lifecell Corporation | Methods for introduction of flowable acellular tissue matrix products into a hand |
-
2018
- 2018-10-18 WO PCT/US2018/056473 patent/WO2019079570A1/en not_active Ceased
- 2018-10-18 JP JP2020514959A patent/JP7297739B2/ja active Active
- 2018-10-18 US US16/164,177 patent/US10821205B2/en active Active
- 2018-10-18 EP EP24213538.2A patent/EP4541385A3/en active Pending
- 2018-10-18 CN CN202210669481.XA patent/CN115252910A/zh active Pending
- 2018-10-18 AU AU2018351051A patent/AU2018351051A1/en not_active Abandoned
- 2018-10-18 CN CN201880065592.1A patent/CN111201046B/zh active Active
- 2018-10-18 EP EP18800384.2A patent/EP3697460A1/en not_active Withdrawn
- 2018-10-18 CA CA3075099A patent/CA3075099A1/en active Pending
-
2020
- 2020-10-16 US US17/072,207 patent/US20210038767A1/en not_active Abandoned
-
2023
- 2023-06-14 JP JP2023097529A patent/JP7559144B2/ja active Active
-
2024
- 2024-06-28 US US18/758,456 patent/US20250065018A1/en active Pending
- 2024-07-26 AU AU2024205150A patent/AU2024205150A1/en not_active Abandoned
- 2024-09-18 JP JP2024160651A patent/JP7785886B2/ja active Active
-
2025
- 2025-11-10 AU AU2025263895A patent/AU2025263895A1/en active Pending
- 2025-12-03 JP JP2025225787A patent/JP2026062652A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101161298A (zh) * | 2007-11-20 | 2008-04-16 | 郑隆泗 | 一种以明胶为原料制备明胶海绵颗粒栓塞剂的工艺 |
| CN101574539A (zh) * | 2009-06-15 | 2009-11-11 | 北京大学 | 一种明胶海绵及其制备方法 |
| CN102575229A (zh) * | 2009-08-11 | 2012-07-11 | 约翰霍普金斯大学 | 用于植入经加工的脂肪组织和经加工的脂肪组织产品的组合物和方法 |
| CN101991875A (zh) * | 2010-10-29 | 2011-03-30 | 上海硅健生物材料有限公司 | 介孔生物活性玻璃和壳聚糖复合多孔止血材料及制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4541385A2 (en) | 2025-04-23 |
| US10821205B2 (en) | 2020-11-03 |
| WO2019079570A1 (en) | 2019-04-25 |
| JP2026062652A (ja) | 2026-04-10 |
| JP7297739B2 (ja) | 2023-06-26 |
| CN111201046A (zh) | 2020-05-26 |
| AU2018351051A1 (en) | 2020-03-19 |
| JP2025011092A (ja) | 2025-01-23 |
| AU2025263895A1 (en) | 2025-12-04 |
| EP4541385A3 (en) | 2025-06-25 |
| US20250065018A1 (en) | 2025-02-27 |
| AU2024205150A1 (en) | 2024-08-15 |
| CA3075099A1 (en) | 2019-04-25 |
| EP3697460A1 (en) | 2020-08-26 |
| CN111201046B (zh) | 2022-06-28 |
| JP7785886B2 (ja) | 2025-12-15 |
| JP2023123578A (ja) | 2023-09-05 |
| US20210038767A1 (en) | 2021-02-11 |
| JP7559144B2 (ja) | 2024-10-01 |
| US20190111183A1 (en) | 2019-04-18 |
| JP2021500091A (ja) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111201046B (zh) | 脂肪组织产品以及产生方法 | |
| Xia et al. | Decellularized cartilage as a prospective scaffold for cartilage repair | |
| US11123375B2 (en) | Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products | |
| US20240226375A1 (en) | Flowable acellular tissue matrix products and methods of production | |
| US20230211048A1 (en) | Biologic breast implant | |
| US11246994B2 (en) | Methods for introduction of flowable acellular tissue matrix products into a hand | |
| WO2021003321A1 (en) | Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products | |
| WO2021202965A1 (en) | Adipose tissue matrix with tropoelastin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |